Revance Therapeutics Inc (RVNC) Stock: More Strategic Than Meets the Eye

Mizuho has recently reduced Revance Therapeutics Inc (RVNC) stock to Neutral rating, as announced on January 29, 2024, according to Finviz. Earlier, on January 9, 2024, Goldman had reduced the stock from a Buy to Neutral, setting a price target of $8 for RVNC stock. Exane BNP Paribas also raised Neutral rating with a price […]

Goldman Sachs Group Inc (GS) Stock: Greater Than Its Current Valuation?

Seaport Research Partners has recently reduced Goldman Sachs Group Inc (GS) stock to Neutral rating, as announced on July 2, 2024, according to Finviz. Earlier, on April 16, 2024, Argus had raised the stock from a Hold to Buy, setting a price target of $465. Daiwa Securities also raised Outperform rating with a price target […]

Blend Labs Inc (BLND) Stock Rated Buy by Canaccord Genuity

Canaccord Genuity has recently raised Blend Labs Inc (BLND) stock to Buy rating, as announced on August 12, 2024, according to Finviz. Earlier, on August 9, 2024, William Blair had raised the stock from a Mkt Perform to Outperform. Wells Fargo also raised Overweight rating with a price target of $3.50. Additionally, Keefe Bruyette raised […]

Vimeo Inc (VMEO) Stock: More Robust Than the Numbers Suggest?

Jefferies has recently reduced Vimeo Inc (VMEO) stock to Hold rating, as announced on January 5, 2024, according to Finviz. Earlier, on May 6, 2022, Piper Sandler had reduced the stock from a Overweight to Neutral, setting a price target of $10 for VMEO stock. JP Morgan also reiterated Neutral rating with a price target […]

Omega Healthcare Investors Inc (OHI) Stock: A Deeper Look at Its True Potential

Mizuho has recently reduced Omega Healthcare Investors Inc (OHI) stock to Neutral rating, as announced on July 25, 2024, according to Finviz. Earlier, on March 22, 2024, Citigroup had raised the stock from a Neutral to Buy, setting a price target of $35 for OHI stock. Wells Fargo also raised Overweight rating with a price […]